Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy
The value of combined L-( methyl -[ 11 C]) methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients w...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-01-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012116687651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563146104340480 |
|---|---|
| author | Kai R. Laukamp MD Florian Lindemann PhD Matthias Weckesser MD Volker Hesselmann MD Sandra Ligges PhD Johannes Wölfer MD Astrid Jeibmann MD Bastian Zinnhardt PhD Thomas Viel PhD Michael Schäfers MD Werner Paulus MD Walter Stummer MD Otmar Schober PhD, MD Andreas H. Jacobs MD |
| author_facet | Kai R. Laukamp MD Florian Lindemann PhD Matthias Weckesser MD Volker Hesselmann MD Sandra Ligges PhD Johannes Wölfer MD Astrid Jeibmann MD Bastian Zinnhardt PhD Thomas Viel PhD Michael Schäfers MD Werner Paulus MD Walter Stummer MD Otmar Schober PhD, MD Andreas H. Jacobs MD |
| author_sort | Kai R. Laukamp MD |
| collection | DOAJ |
| description | The value of combined L-( methyl -[ 11 C]) methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients with histologically verified brain lesions n = 70 MET-PET and MRI (T1-weighted gadolinium-enhanced [T1w-Gd] and fluid-attenuated inversion recovery or T2-weighted [FLAIR/T2w]) examinations were performed. The computer software “visualization and analysis framework volume rendering engine (Voreen)” was used for analysis of extent and intersection of tumor compartments. Binary logistic regression models were developed to differentiate between World Health Organization (WHO) tumor types/grades. Tumor sizes as defined by thresholding based on tumor-to-background ratios were significantly different as determined by MET-PET (21.6 ± 36.8 cm 3 ), T1w-Gd-MRI (3.9 ± 7.8 cm 3 ), and FLAIR/T2-MRI (64.8 ± 60.4 cm 3 ; P < .001). The MET-PET visualized tumor activity where MRI parameters were negative: PET positive tumor volume without Gd enhancement was 19.8 ± 35.0 cm 3 and without changes in FLAIR/T2 10.3 ± 25.7 cm 3 . FLAIR/T2-MRI visualized greatest tumor extent with differences to MET-PET being greater in posttherapy (64.6 ± 62.7 cm 3 ) than in newly diagnosed patients (20.5 ± 52.6 cm 3 ). The binary logistic regression model differentiated between WHO tumor types (fibrillary astrocytoma II n = 10 from other gliomas n = 16) with an accuracy of 80.8% in patients at primary diagnosis. Combined PET and MRI improve the evaluation of tumor activity, extent, type/grade prediction, and therapy-induced changes in patients with glioma and serve information highly relevant for diagnosis and management. |
| format | Article |
| id | doaj-art-68b31cee72ac4d75a2474bd3659e63f7 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-68b31cee72ac4d75a2474bd3659e63f72025-01-03T00:11:23ZengSAGE PublishingMolecular Imaging1536-01212017-01-011610.1177/153601211668765110.1177_1536012116687651Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After TherapyKai R. Laukamp MD0Florian Lindemann PhD1Matthias Weckesser MD2Volker Hesselmann MD3Sandra Ligges PhD4Johannes Wölfer MD5Astrid Jeibmann MD6Bastian Zinnhardt PhD7Thomas Viel PhD8Michael Schäfers MD9Werner Paulus MD10Walter Stummer MD11Otmar Schober PhD, MD12Andreas H. Jacobs MD13 Department of Radiology, University Hospital of Cologne, Cologne, Germany Department of Computer Science, Visualization and Computer Graphics Research Group, Westfälische Wilhelms-Universität Münster, Munster, Germany Departments of Nuclear Medicine, Westfälische Wilhelms-Universität Münster, Munster, Germany Departments of Radiology, Westfälische Wilhelms-Universität Münster, Munster, Germany Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Munster, Germany Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Munster, Germany Department of Neuropathology, Westfälische Wilhelms-Universität Münster, Munster, Germany European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Munster, Germany European Institute for Molecular Imaging, Westfälische Wilhelms-Universität Münster, Munster, Germany Cells-in-Motion Cluster of Excellence (EXC 1003–CiM), Westfälische Wilhelms-Universität Münster, Munster, Germany Cells-in-Motion Cluster of Excellence (EXC 1003–CiM), Westfälische Wilhelms-Universität Münster, Munster, Germany Cells-in-Motion Cluster of Excellence (EXC 1003–CiM), Westfälische Wilhelms-Universität Münster, Munster, Germany Cells-in-Motion Cluster of Excellence (EXC 1003–CiM), Westfälische Wilhelms-Universität Münster, Munster, Germany Department of Geriatric Medicine, Johanniter Hospital, Evangelische Kliniken, Bonn, GermanyThe value of combined L-( methyl -[ 11 C]) methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients with histologically verified brain lesions n = 70 MET-PET and MRI (T1-weighted gadolinium-enhanced [T1w-Gd] and fluid-attenuated inversion recovery or T2-weighted [FLAIR/T2w]) examinations were performed. The computer software “visualization and analysis framework volume rendering engine (Voreen)” was used for analysis of extent and intersection of tumor compartments. Binary logistic regression models were developed to differentiate between World Health Organization (WHO) tumor types/grades. Tumor sizes as defined by thresholding based on tumor-to-background ratios were significantly different as determined by MET-PET (21.6 ± 36.8 cm 3 ), T1w-Gd-MRI (3.9 ± 7.8 cm 3 ), and FLAIR/T2-MRI (64.8 ± 60.4 cm 3 ; P < .001). The MET-PET visualized tumor activity where MRI parameters were negative: PET positive tumor volume without Gd enhancement was 19.8 ± 35.0 cm 3 and without changes in FLAIR/T2 10.3 ± 25.7 cm 3 . FLAIR/T2-MRI visualized greatest tumor extent with differences to MET-PET being greater in posttherapy (64.6 ± 62.7 cm 3 ) than in newly diagnosed patients (20.5 ± 52.6 cm 3 ). The binary logistic regression model differentiated between WHO tumor types (fibrillary astrocytoma II n = 10 from other gliomas n = 16) with an accuracy of 80.8% in patients at primary diagnosis. Combined PET and MRI improve the evaluation of tumor activity, extent, type/grade prediction, and therapy-induced changes in patients with glioma and serve information highly relevant for diagnosis and management.https://doi.org/10.1177/1536012116687651 |
| spellingShingle | Kai R. Laukamp MD Florian Lindemann PhD Matthias Weckesser MD Volker Hesselmann MD Sandra Ligges PhD Johannes Wölfer MD Astrid Jeibmann MD Bastian Zinnhardt PhD Thomas Viel PhD Michael Schäfers MD Werner Paulus MD Walter Stummer MD Otmar Schober PhD, MD Andreas H. Jacobs MD Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy Molecular Imaging |
| title | Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy |
| title_full | Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy |
| title_fullStr | Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy |
| title_full_unstemmed | Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy |
| title_short | Multimodal Imaging of Patients With Gliomas Confirms C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy |
| title_sort | multimodal imaging of patients with gliomas confirms c met pet as a complementary marker to mri for noninvasive tumor grading and intraindividual follow up after therapy |
| url | https://doi.org/10.1177/1536012116687651 |
| work_keys_str_mv | AT kairlaukampmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT florianlindemannphd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT matthiasweckessermd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT volkerhesselmannmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT sandraliggesphd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT johanneswolfermd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT astridjeibmannmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT bastianzinnhardtphd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT thomasvielphd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT michaelschafersmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT wernerpaulusmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT walterstummermd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT otmarschoberphdmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy AT andreashjacobsmd multimodalimagingofpatientswithgliomasconfirmscmetpetasacomplementarymarkertomrifornoninvasivetumorgradingandintraindividualfollowupaftertherapy |